Aralez Pharmaceuticals (ARLZ) Receiving Somewhat Favorable News Coverage, Study Shows

Media coverage about Aralez Pharmaceuticals (NASDAQ:ARLZ) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Aralez Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.4015411214576 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Aralez Pharmaceuticals (NASDAQ ARLZ) opened at $1.44 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.92 and a debt-to-equity ratio of 4.64. Aralez Pharmaceuticals has a one year low of $0.95 and a one year high of $4.90.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its earnings results on Thursday, November 9th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.02. Aralez Pharmaceuticals had a negative net margin of 112.89% and a negative return on equity of 118.13%. The company had revenue of $24.30 million for the quarter, compared to the consensus estimate of $22.87 million. During the same period in the previous year, the firm earned ($0.32) earnings per share. The firm’s revenue for the quarter was up 78.7% on a year-over-year basis. research analysts forecast that Aralez Pharmaceuticals will post -1.54 EPS for the current year.

In related news, Director Arthur S. Kirsch purchased 50,000 shares of the business’s stock in a transaction that occurred on Friday, December 8th. The shares were acquired at an average price of $1.47 per share, for a total transaction of $73,500.00. Following the completion of the acquisition, the director now directly owns 271,609 shares in the company, valued at approximately $399,265.23. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.70% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Aralez Pharmaceuticals (ARLZ) Receiving Somewhat Favorable News Coverage, Study Shows” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://sportsperspectives.com/2017/12/20/aralez-pharmaceuticals-arlz-receiving-somewhat-favorable-news-coverage-study-shows.html.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Insider Buying and Selling by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply